S'abonner

Patterns of IgE responses to multiple allergen components and clinical symptoms at age 11 years - 06/11/15

Doi : 10.1016/j.jaci.2015.03.027 
Angela Simpson, MD, PhD a, , Nevena Lazic, PhD b, , §, Danielle C.M. Belgrave, PhD a, c, Phil Johnson, PhD a, d, Christopher Bishop, PhD b, Clare Mills, PhD a, d, , Adnan Custovic, MD, PhD a,
a Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, University of Manchester & University Hospital of South Manchester, Manchester, United Kingdom 
b Microsoft Research Cambridge, Cambridge, United Kingdom 
c Centre for Health Informatics, Institute of Population Health, University of Manchester, Manchester, United Kingdom 
d Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Institute of Biotechnology, University of Manchester, Manchester, United Kingdom 

Corresponding author: Angela Simpson, MD, PhD, University of Manchester, ERC Building, Second floor, University Hospital of South Manchester, Manchester M23 9LT, United Kingdom.

Abstract

Background

The relationship between sensitization to allergens and disease is complex.

Objective

We sought to identify patterns of response to a broad range of allergen components and investigate associations with asthma, eczema, and hay fever.

Methods

Serum specific IgE levels to 112 allergen components were measured by using a multiplex array (Immuno Solid-phase Allergen Chip) in a population-based birth cohort. Latent variable modeling was used to identify underlying patterns of component-specific IgE responses; these patterns were then related to asthma, eczema, and hay fever.

Results

Two hundred twenty-one of 461 children had IgE to 1 or more components. Seventy-one of the 112 components were recognized by 3 or more children. By using latent variable modeling, 61 allergen components clustered into 3 component groups (CG1, CG2, and CG3); protein families within each CG were exclusive to that group. CG1 comprised 27 components from 8 plant protein families. CG2 comprised 7 components of mite allergens from 3 protein families. CG3 included 27 components of plant, animal, and fungal origin from 12 protein families. Each CG included components from different biological sources with structural homology and also nonhomologous proteins arising from the same biological source. Sensitization to CG3 was most strongly associated with asthma (odds ratio [OR], 8.20; 95% CI, 3.49-19.24; P < .001) and lower FEV1 (P < .001). Sensitization to CG1 was associated with hay fever (OR, 12.79; 95% CI, 6.84-23.90; P < .001). Sensitization to CG2 was associated with both asthma (OR, 3.60; 95% CI, 2.05-6.29) and hay fever (OR, 2.52; 95% CI, 1.38-4.61).

Conclusions

Latent variable modeling with a large number of allergen components identified 3 patterns of IgE responses, each including different protein families. In 11-year-old children the pattern of response to components of multiple allergens appeared to be associated with current asthma and hay fever but not eczema.

Le texte complet de cet article est disponible en PDF.

Key words : IgE, childhood, component-resolved diagnostics, latent variable modeling, allergens, asthma, wheeze, eczema, hay fever

Abbreviations used : CG, CRD, eNO, ISAC, ISU, OR, sIgE


Plan


 Supported by Asthma UK (301, 362, 01/012, 04/014), the JP Moulton Charitable Foundation, the Medical Research Council (grants G0601361 and MR/K002449/1), and the North West Lung Centre Charity.
 Disclosure of potential conflict of interest: A. Simpson has received research support from the Medical Research Council (G0601361 and MR/K002449/1), the JP Moulton Charitable Foundation, Thermo Fisher Scientific, EU FP7 Grant agreement no. 312147, and the National Institute for Health Research; has received speaker fees from GlaxoSmithKline, Thermo Fisher Scientific, and Chiesi; and has received travel support from GlaxoSmithKline. D. C. M. Belgrave is employed by GlaxoSmithKline. C. Mills is founding director of and member of the board of Reacta Biotech Ltd (a company commercializing oral food challenges) and has received research support from Reacta Biotech, the UK Biological and Biotechnological Sciences Research Council, DBV Technologies, Novartis, and the Medical Research Council. A. Custovic has received research support from the Medical Research Council (G0601361 and MR/K002449/1), the JP Moulton Charitable Foundation, North West Lung Research Centre Charity, European Union 7th Framework Programme Grant agreement no. 312147, and the National Institute for Health Research and has received personal fees from Novartis, Thermo Fisher, AstraZeneca, ALK-Abelló, and GlaxoSmithKline. The rest of the authors declare that they have no relevant conflicts of interest.


© 2015  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 136 - N° 5

P. 1224-1231 - novembre 2015 Retour au numéro
Article précédent Article précédent
  • Effect of pregnancy in asthma on health care use and perinatal outcomes
  • Sujeong Kim, Jinhee Kim, So Young Park, Hye-Yeon Um, Kyoungjoo Kim, Yuri Kim, Yunjin Park, Seunghee Baek, Sun-Young Yoon, Hyouk-Soo Kwon, You Sook Cho, Hee-Bom Moon, Tae-Bum Kim
| Article suivant Article suivant
  • Prostaglandin E2 inhibits mast cell–dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor
  • Jesper Säfholm, Martijn L. Manson, Johan Bood, Ingrid Delin, Ann-Charlotte Orre, Per Bergman, Mamdoh Al-Ameri, Sven-Erik Dahlén, Mikael Adner

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.